dendrit
cell
dc
key
regul
adapt
tcell
respons
captur
exogen
antigen
present
antigenderiv
peptid
via
major
histocompat
complex
molecul
cell
dc
induc
antigenspecif
immun
respons
vivo
order
induc
effect
host
immun
respons
activ
deliveri
exogen
antigen
dc
consid
import
futur
vaccin
develop
recent
gener
bionanocapsul
bnc
consist
hepat
b
viru
surfac
antigen
mediat
stringent
vivo
cell
target
effici
endosom
escap
fusion
liposom
lp
contain
therapeut
materi
bnclp
complex
deliv
human
liverderiv
tissu
vivo
bnc
modifi
present
immunoglobulin
g
igg
fcinteract
domain
z
domain
deriv
staphylococcu
aureu
protein
tandem
mix
igg
modifi
bnc
zzbnc
display
igg
fv
region
outwardli
effici
bind
antigen
orientedimmobil
manner
due
affin
display
igg
iggzzbnc
complex
accumul
specif
cell
tissu
vitro
vivo
mix
zzbnc
antibodi
dc
use
immunocytochemistri
examin
antibodi
deliv
zzbnc
mous
splenic
dc
follow
intraven
inject
zzbnc
zzbnc
display
monoclon
antibodi
found
accumul
approxim
splenic
dc
resid
within
fusion
liposom
contain
antigen
could
elicit
respect
antibodi
effici
nontarget
control
vaccin
suggest
dcspecif
nanocarri
promis
futur
vaccin
coronaviru
lentiviru
display
sindbi
viru
glycoprotein
use
dcspecif
gene
deliveri
howev
vector
present
potenti
problem
commonli
observ
viral
vector
includ
unexpect
immunolog
respons
patient
accident
disturb
patient
chromosom
unaccept
ag
dna
nonvir
vector
also
util
deliv
ag
dc
nanoparticl
consist
poli
acid
could
target
dc
passiv
system
administr
micel
consist
poli
ethylen
glycol
base
amphipath
polym
accumul
nearli
dc
drain
lymph
node
follow
intraderm
inject
liposom
lp
ag
modifi
fv
form
bacteri
flagellinrel
peptid
mannos
could
target
dc
effici
passiv
target
due
specif
interact
dc
surfac
molecul
although
nonvir
vector
may
part
solv
viral
vectorrel
problem
describ
potenti
lack
mechan
infect
endosom
escap
eg
membran
fusiogen
domain
viral
envelop
protein
lead
reduc
immunogen
ag
due
low
recognit
effici
dc
therefor
necessari
endow
nonvir
vector
target
abil
membran
fusiogen
activ
order
develop
effect
dctarget
nanocarri
futur
vaccin
bionanocapsul
bnc
approxim
hollow
nanoparticl
consist
molecul
hepat
b
viru
hbv
surfac
antigen
hbsag
l
protein
unilamellar
lp
bnc
produc
effici
recombin
yeast
engin
express
l
protein
bnc
specif
attach
human
hepat
cell
via
ntermin
half
l
protein
region
enter
cell
rate
hbv
follow
encapsul
variou
materi
eg
gene
protein
chemic
compound
electropor
liposom
fusion
bnc
deliv
specif
human
hepat
cell
vitro
also
vivo
replac
central
part
region
amino
acid
residu
bnc
tandem
form
igg
fcinteract
region
z
domain
deriv
staphylococcu
aureu
protein
gener
zzl
protein
figur
mutat
bnc
zzbnc
tether
igg
fc
region
display
igg
fv
region
outwardli
effect
bind
ag
orientedimmobil
manner
figur
retain
membran
fusiogen
activ
zzbnc
display
growth
factor
receptor
egfr
antibodi
effici
target
egfroverexpress
glioblastoma
vivo
follow
intracerebroventricular
inject
properti
zzbnc
may
use
activ
target
introduct
ag
dc
make
dcmediat
vaccin
promis
approach
studi
zzbnc
display
antibodi
evalu
target
introduct
splenic
dc
vitro
vivo
could
use
dcspecif
nanocarri
follow
fusion
lp
contain
antigen
bnc
zzbnc
overexpress
saccharomyc
cerevisia
carri
bncand
zzbncexpress
plasmid
respect
bnc
zzbnc
purifi
describ
previous
number
igg
molecul
bound
zzbnc
determin
quartz
crystal
microbal
qcm
model
twinq
one
corp
osaka
japan
describ
previous
briefli
sensor
chip
qcm
consist
disk
made
atcut
quartz
crystal
gold
electrod
side
diamet
mm
area
mm
frequenc
chang
hz
correspond
weight
chang
ngcm
temperatur
measur
bath
kept
bath
mix
rpm
stir
tube
measur
taken
triplic
stabl
frequenc
less
hz
observ
minut
protein
sampl
dissolv
phosphatebuff
salin
pb
sensor
chip
treat
zzbnc
protein
block
block
ace
mgml
ds
pharma
biomed
osaka
japan
react
igg
isotyp
control
display
igg
surfac
zzbnc
carri
chemic
crosslink
describ
previous
briefli
igg
crosslink
zzbnc
protein
presenc
bissulfosuccinimidyl
suber
bs
pierc
incub
room
temperatur
hour
glycin
ph
ad
quench
crosslink
reaction
splenic
dc
isol
balbc
femal
mice
six
eight
week
japan
slc
shizuoka
japan
briefli
spleen
treat
gentlemac
tm
dissoci
miltenyi
biotech
presenc
mgml
collagenas
roch
mannheim
germani
cell
purifi
splenocyt
magnet
cell
sort
mac
miltenyi
biotech
use
fcr
block
reagent
clone
label
magnet
bead
cell
popul
contain
cell
use
splenic
dc
experi
dc
cell
mix
complex
zzl
protein
incub
minut
analyz
flow
cytomet
bd
facscan
canto
ii
bd
bioscienc
san
jose
ca
linear
amplif
forwardsid
scatter
logarithm
amplif
fitc
fluoresc
fitcderiv
fluoresc
emiss
nm
excit
laser
fluoresc
emiss
nm
excit
laser
mous
inject
intraven
pb
contain
protein
zzbnc
conjug
igg
minut
mice
sacrif
fluoresc
signal
heart
lung
kidney
liver
spleen
measur
use
vivo
imag
system
olympu
tokyo
japan
fluoresc
emiss
nm
excit
xenon
lamp
emiss
filter
nm
obtain
interfer
barrier
filter
semiquantifi
accumul
complex
organ
fluoresc
signal
measur
use
wasabi
softwar
hamamatsu
photon
shizuoka
japan
complex
zzl
protein
inject
mice
intraven
minut
mice
sacrif
splenocyt
dissoci
mac
buffer
gentlemac
tm
dissoci
aliquot
cell
suspens
cell
mix
incub
minut
wash
three
time
mac
buffer
evalu
dctarget
bnc
cell
subject
quantit
analysi
use
flow
cytomet
bd
facscan
canto
ii
linear
amplif
forwardsid
scatter
logarithm
amplif
fitc
fluoresc
submit
manuscript
wwwdovepresscom
subcellular
local
complex
analyz
confoc
laser
scan
microscop
lsm
model
olympu
whole
cell
zstack
slice
total
section
acquir
lsm
equip
oil
object
len
olympu
immun
mice
complex
contain
jev
envelopederiv
antigen
japanes
enceph
viru
jev
envelopederiv
antigen
express
escherichia
coli
purifi
describ
previous
antigen
mix
zzbnclp
complex
zzl
protein
lp
incub
room
temperatur
hour
antibodi
clone
conjug
onto
surfac
complex
see
section
prepar
complex
aliquot
complex
antigen
administr
mous
balbc
femal
week
japan
slc
intraven
week
booster
immun
carri
complex
antigen
blood
sampl
collect
tail
vein
determin
serum
igg
week
first
immun
enzymelink
immunosorb
assay
elisa
serum
igg
titer
serum
igg
measur
indirect
elisa
describ
previous
briefli
microtit
plate
nalg
nunc
intern
rochest
ny
coat
e
coliexpress
recombin
protein
block
wv
skim
milk
bicarbon
buffer
serial
dilut
antisera
horseradish
peroxidas
hrp
conjug
rabbit
antimous
igg
sigmaaldrich
st
loui
mo
ad
well
follow
hrp
substrat
minut
incub
room
temperatur
reaction
stop
ad
n
sulfur
acid
absorb
measur
nm
use
micropl
reader
biorad
laboratori
redmond
wa
prepar
armenian
hamster
igg
observ
bound
zzbnc
high
affin
mol
per
mol
zzl
protein
rat
weakli
bound
zzbnc
mol
per
mol
zzl
protein
respect
gener
stabl
complex
chemic
crosslink
bs
ad
mixtur
zzbnc
antibodi
describ
previous
shown
tabl
zaverag
complex
less
nm
recent
group
demonstr
fluorophorelabel
zzbnc
complex
versatil
bioimag
probe
immunocytochem
analys
display
igg
fv
region
outwardli
effect
bind
ag
zzbnc
mix
five
antibodi
crosslink
bs
ad
suspens
splenic
dc
flow
cytometr
analys
show
zzbnc
display
antibodi
clone
class
ii
antibodi
accumul
splenic
dc
respect
figur
antibodi
unexpectedli
show
lower
extent
accumul
similar
mous
igg
zzbnc
alon
higher
bnc
alon
result
confirm
mean
fluoresc
intens
dc
incub
complex
figur
differ
dc
accumul
among
antibodi
may
caus
either
number
antibodi
zzbnc
affin
antibodi
dc
cell
surfac
molecul
splenic
dc
show
high
affin
igg
zz
domain
zzbnc
display
mous
igg
zzbnc
alon
may
accumul
dc
furthermor
sinc
bnc
zzbnc
possess
highmannos
sugar
chain
mannos
receptor
dc
may
contribut
interact
vivo
distribut
zzbnc
display
clone
class
ii
antibodi
label
inject
tail
vein
mice
approxim
zzl
protein
per
mous
complex
excret
bladder
within
minut
inject
judg
complex
circul
throughout
whole
bodi
minut
inject
mice
sacrif
minut
inject
subject
extirp
heart
lung
kidney
liver
spleen
organ
observ
fluoresc
vivo
imag
system
shown
figur
zzbnc
bnc
found
local
liver
spleen
preferenti
spleen
contain
larger
number
lymphoidresid
dc
liver
splenic
dc
induc
higher
immun
respons
exogen
ag
hepat
dc
select
splenic
dc
target
studi
among
complex
clone
antibodi
deliv
zzbnc
spleen
highest
specif
figur
c
mous
total
igg
class
ii
antibodi
zz
domain
could
also
deliv
zzbnc
spleen
extent
suggest
molecul
affin
splenic
dc
describ
previous
vivo
attach
splenic
dc
zzbnc
display
clone
antibodi
class
ii
antibodi
mous
total
igg
inject
mice
intraven
zzl
protein
per
mous
minut
inject
mice
sacrif
spleen
extirp
splenocyt
isol
use
gentlemac
tm
dissoci
analyz
flow
cytometri
figur
clone
zzbnc
complex
detect
approxim
splenocyt
zzbnc
complex
zzbnc
bnc
detect
lower
popul
splenocyt
moreov
sinc
clone
zzbnc
complex
detect
figur
determin
complex
high
specif
splenic
cell
vivo
next
cell
purifi
splenocyt
magnet
cell
sort
mac
use
magnet
bead
stain
immunocytochem
fitclabel
antibodi
observ
lsm
figur
zzbnc
coloc
mean
sd
n
cell
zstack
project
cell
contain
zzbnc
gener
deconvolv
slice
use
maximum
intens
criteria
indic
intraven
inject
clone
zzbnc
complex
immedi
incorpor
splenic
dc
lymphocyt
choriomening
viral
vector
inject
mice
intraven
viral
particl
accumul
splenic
dc
day
inject
lp
display
bacteri
flagellinrel
peptid
could
accumul
splenic
dc
hour
intraven
inject
moreov
f
ab
fuse
ag
could
accumul
splenic
dc
hour
subcutan
inject
result
demonstr
complex
could
promptli
effici
accumul
splenic
dc
splenocyt
minut
intraven
inject
dctarget
nanocarri
zzbnc
could
display
antibodi
orientedimmobil
manner
therebi
significantli
enhanc
sensit
antigenbind
capac
affin
antibodi
complex
format
antibodi
zzbnc
may
improv
molecular
recognit
molecul
dctarget
nanocarri
immun
mice
complex
zzbnc
inject
intraven
affect
morpholog
cytokin
secret
mous
splenocyt
significantli
data
shown
led
us
examin
efficaci
complex
deliv
antigen
splenic
dc
cell
vivo
bnc
shown
form
stabl
complex
lp
spontan
deliv
complex
celland
tissuespecif
manner
vivo
vivo
mix
zzbnc
cation
lp
zzbnclp
complex
purifi
cscl
isopycn
ultracentrifug
follow
dialysi
pb
complex
consist
zzl
protein
lp
zaverag
diamet
nm
polydispers
index
pdi
mv
respect
evalu
vivo
deliveri
specif
splenic
dc
chose
domain
iii
jev
envelop
protein
control
ag
antigen
express
e
coli
subsequ
purifi
describ
previous
zzbnclp
complex
zzl
protein
lp
allow
conjug
antigen
electrostat
interact
display
antibodi
clone
complex
zaverag
complex
complex
complex
nm
pdi
nm
pdi
nm
pdi
mv
mv
mv
respect
diamet
complex
suitabl
system
administr
conjug
lp
increas
diamet
greater
nm
howev
spleen
readili
captur
nanoparticl
nm
diamet
bloodstream
consid
complex
could
deliv
antigen
splenic
dc
effici
follow
intraven
inject
mice
immun
intraven
clone
complex
antigen
per
mous
without
adjuv
twice
interv
alon
complex
complex
use
control
vaccin
control
vaccin
contain
antigen
inject
mous
way
week
first
immun
blood
sampl
collect
tail
vein
determin
serum
igg
elisa
figur
week
signific
elicit
igg
observ
mous
complex
elicit
high
titer
igg
week
control
vaccin
contain
amount
antigen
clone
zzbnc
accumul
splenic
dc
vivo
follow
intraven
inject
see
figur
strongli
suggest
complex
abl
effect
deliv
antigen
insid
splenic
dc
sever
line
evid
recent
indic
dc
target
mediat
superior
mediat
molecul
human
monocyt
includ
dc
molecul
form
heterodim
molecul
also
known
complement
receptor
mediat
phagocytosi
complex
may
facilit
effici
uptak
antigen
dc
lead
effect
induct
immun
respons
moreov
report
f
ab
ag
accumul
splenic
margin
zone
follow
intraven
inject
migrat
splenic
cell
zone
class
ii
f
ab
ag
accumul
splenic
b
cell
zone
result
strongli
suggest
dc
splenic
margin
zone
stimul
ag
manner
migrat
splenic
cell
zone
taken
togeth
complex
postul
accumul
splenic
dc
stimul
dc
antigen
move
dc
margin
zone
cell
zone
present
fragment
antigen
mhc
molecul
cell
along
costimul
factor
eg
induc
immun
respons
includ
product
igg
regard
administr
rout
rare
administ
vaccin
intraven
evalu
whether
vaccin
platform
could
target
migratori
dc
eg
langerhan
cell
mice
intramuscular
subcutan
administr
zzbnc
scaffold
display
igg
orientedimmobil
manner
thu
enhanc
sensit
antigenbind
capac
affin
igg
studi
evalu
zzbnc
display
antibodi
clone
vivo
dctarget
follow
intraven
inject
mice
complex
accumul
splenic
dc
incorpor
dc
immedi
complex
use
probe
vivo
imag
dc
furthermor
complex
load
jev
antigen
could
elicit
igg
effici
nontarget
control
vaccin
suggest
dcspecif
nanocarri
promis
futur
vaccin
